Department of Chemistry and Applied Biosciences, Institute for Chemical and Bioengineering, Swiss Federal Institute of Technology , Zurich, Switzerland.
Department of Biophysics, Biophysics and Injectable Formulation, Novo Nordisk , Måløv, Denmark.
MAbs. 2020 Jan-Dec;12(1):1815995. doi: 10.1080/19420862.2020.1815995.
High physical stability is required for the development of monoclonal antibodies (mAbs) into successful therapeutic products. Developability assays are used to predict physical stability issues such as high viscosity and poor conformational stability, but protein aggregation remains a challenging property to predict. Among different types of stresses, air-water and solid-liquid interfaces are well known to potentially trigger protein instability and induce aggregation. Yet, in contrast to the increasing number of developability assays to evaluate bulk properties, there is still a lack of experimental methods to evaluate antibody stability against interfaces. Here, we investigate the potential of a hydrophobic nanoparticle surface-mediated stress assay to assess the stability of mAbs during the early stages of development. We evaluate this surface-mediated accelerated stability assay on a rationally designed library of 14 variants of a humanized IgG4, featuring a broad span of solubility values and other developability properties. The assay could identify variants characterized by high instability against agitation in the presence of air-water interfaces. Remarkably, for the set of investigated molecules, we observe strong correlations between the extent of aggregation induced by the surface-mediated stress assay and other developability properties of the molecules, such as aggregation upon storage at 45°C, self-association (evaluated by affinity-capture self-interaction nanoparticle spectroscopy) and nonspecific interactions (estimated by cross-interaction chromatography, stand-up monolayer chromatography (SMAC), SMAC*). This highly controlled surface-mediated stress assay has the potential to complement and increase the ability of the current set of screening techniques to assess protein aggregation and developability potential of mAbs during the early stages of drug development. :AC-SINS: Affinity-Capture Self-Interaction Nanoparticle Spectroscopy; AMS: Ammonium sulfate precipitation; ANS: 1-anilinonaphtalene-8-sulfonate; CIC: Cross-interaction chromatography; DLS: Dynamic light scattering; HIC: Hydrophobic interaction chromatography; HNSSA: Hydrophobic nanoparticles surface-stress assay; mAb: Monoclonal antibody; NP: Nanoparticle; SEC: Size exclusion chromatography; SMAC: Stand-up monolayer chromatography; WT: Wild type.
高度的物理稳定性是将单克隆抗体(mAbs)开发成成功的治疗产品的必要条件。可开发性测定用于预测物理稳定性问题,如高粘度和较差的构象稳定性,但蛋白质聚集仍然是一个具有挑战性的难以预测的性质。在不同类型的压力下,气-水和固-液界面众所周知可能会引发蛋白质不稳定并导致聚集。然而,与评估总体性质的可开发性测定数量不断增加相比,仍然缺乏评估抗体对界面稳定性的实验方法。在这里,我们研究了疏水性纳米颗粒表面介导的应激测定法在 mAb 早期开发阶段评估 mAb 稳定性的潜力。我们在一个经过合理设计的人源化 IgG4 变体文库上评估了这种表面介导的加速稳定性测定法,该文库具有广泛的溶解度值和其他可开发性特性。该测定法可以识别出在存在气-水界面的情况下因搅拌而具有高不稳定性的变体。值得注意的是,对于所研究的分子集合,我们观察到表面介导的应激测定法诱导的聚集程度与分子的其他可开发性特性之间存在强烈的相关性,例如在 45°C 下储存时的聚集、自缔合(通过亲和力捕获自相互作用纳米颗粒光谱法评估)和非特异性相互作用(通过交叉相互作用色谱法、站立单层色谱法(SMAC)、SMAC*估计)。这种高度受控的表面介导的应激测定法有可能补充并提高当前筛选技术的能力,以评估药物开发早期 mAb 的蛋白质聚集和可开发性潜力。:AC-SINS: 亲和力捕获自相互作用纳米颗粒光谱法;AMS: 硫酸铵沉淀;ANS: 1-苯胺-8-萘磺酸盐;CIC: 交叉相互作用色谱法;DLS: 动态光散射;HIC: 疏水相互作用色谱法;HNSSA: 疏水性纳米颗粒表面应激测定法;mAb: 单克隆抗体;NP: 纳米颗粒;SEC: 大小排阻色谱法;SMAC: 站立单层色谱法;WT: 野生型。